Please note that some study locations are now accepting new study participants, however some locations remain closed due to the ongoing impact of Coronavirus (COVID-19). Please continue to check back as we expect to add more study locations as this situation improves and changes.
TRANSCEND CLL 004 may be an option for those who meet the following criteria:
Please note that travel reimbursement may be available as an option so please discuss this with the study site in question. For study site location information, click here to visit clinicaltrials.gov
If you meet the initial criteria above, please take the prescreening questionnaire below to see if you might qualify to participate in this study. If you pass the pre-screener you will have the opportunity to search and provide your contact information to a study site so that you can discuss the study with the study site and arrange for a screening visit, if applicable.
Participation in the study lasts approximately 26 months. This includes:
The investigational study drug used in TRANSCEND CLL 004 is called JCAR017. This drug is the result of a modification to a participant’s own immune cells (T cells) with a chimeric antigen receptor (CAR). These modified T cells (CAR T cells), may target and reduce the number of cancer cells, which then could provide an environment for healthy cells to grow normally. JCAR017 is administered once as an infusion during the treatment period.